U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07808060) titled 'A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight' on Sept. 03.
Brief Summary: The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: Eloralintide
Eloralintide administered SC
DRUG: Combined oral contraceptive...